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This study provides causal evidence on the health and economic consequences of a broad-scope 
vaccination  program.  The  Ontario  Influenza  Immunization  Campaign  (introduced  in  2001) 
expanded  the  scope  of  vaccine  coverage  to  the  full  population.  By  using  the  timing  of  this 
campaign and exogenous variation in vaccine quality, I am able to causally link higher vaccination 
rates to decreases in lost work-time, hospitalization, and death. Results indicate that, when vaccine 
quality is high, the campaign resulted in higher gains for Ontario relative to other provinces and in 
short, an ounce of prevention is worth a pound of cure. Results also suggest significant positive 
health externalities for the elderly. Possible implications for the benefits of a flu vaccine specific to 
H1N1/09 flu are discussed.  
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1 Introduction  
  In the early 20th century, pneumonia, influenza, and other respiratory infections accounted 
for more than a quarter of all deaths, and infectious diseases more generally were the principal 
cause of worldwide mortality. The subsequent decline in infectious disease coincided with an 
epidemiological transition that was in part characterized by the development and use of vaccines. 
This  innovation  led  to  extensive  government  action  consisting  of  vaccination  campaigns, 
regulatory measures, and education. Adoptions of such protocols continue for recently developed 
vaccines and are being considered for the newest form of influenza, the H1N1/09 strain or “swine 
flu.”
1 Relying on standard arguments about the externality effects of preventing infectious disease, 
there  is  substantive  motivation  for  public  action.  Nevertheless,  public  action  in  the  form  of 
immunization  programs  should  rest  on  rigorous  comparison  of  costs  and  benefits.  Program 
evaluation of public campaigns for new and existing vaccines thus requires accurate evaluation of 
the health and economic consequences of such programs. Unfortunately, since there is little known 
about the true impact of vaccination campaigns it remains difficult to compare benefits to upfront 
costs.  
  This study focuses on a broad-based vaccination program targeted toward influenza (the 
flu).  The  Ontario  Universal  Influenza  Immunization  Campaign  was  introduced  in  2001  and 
expanded delivery of free flu shots beyond the traditional target group to include all children and 
adults. Previous to 2001 only high-risk groups including the elderly and those with select chronic 
conditions were eligible to receive the vaccine and recommendations to vaccinate outside this 
target  group  continue  to  be  controversial.
2  The  program  in  Ontario  is  innovative  on  several 
dimensions: it not only recommends the flu shot for all age groups, but it also fully subsidizes the 
cost of the flu shot and its administration. I show that this highly advertised program has led to 
substantial increases in vaccination for the impacted group and has implied substantial increases in 
the overall level of vaccination within Ontario.  
  Since the Ontario campaign was successful at delivering flu shots, it offers a useful policy 
experiment to evaluate the impact of vaccinating children and younger adults against flu. Given 
that a simple before and after comparison for Ontario may incorrectly attribute all changes in 
outcomes to the flu shot campaign and even conventional difference-in-difference comparisons 
                                                 
1 Other examples include: varicella, human papillomavirus, pneumococcal, meningococcal, and hepatitis vaccines. 
2  For  instance,  the  United  Kingdom’s  Department  of  Health  offers  flu  shot  coverage  for  the  standard  target  group  while 
deemphasizing the flu shot for others. Alternatively, the Centre for Disease Control and Prevention (CDC) in the U.S. has recently 
added children under 18 to the target group and is considering further changes to scope.   3 
with  other  provinces  may  be  confounded  with  differential  trends,  I  instead  develop  an 
identification strategy that exploits variation in the match of the flu shot to the flu. This variation is 
plausibly exogenous. The composition of the flu shot is predetermined and fixed for each flu 
season and across all provinces, while the genetic composition of the flu is constantly changing. 
This implies that if there are benefits from vaccination, Ontario relative to the other provinces will 
have more to gain when the flu shot is a good match whereas it will have little to gain when it is 
not. By using this methodology, I am able to disentangle the causal impact of flu shots from 
alternative  explanations  for  differences  in  outcomes  such  as  advertising  effects  related  to  the 
program or any other associated differential trends.
3 Furthermore, since the match of the flu shot is 
unknown  at  the  time  of  vaccination,  changes  in  compensatory  behaviors  arising  from 
immunization are unlikely correlated with the match and thus cannot explain the estimated impact.  
Using weekly data for city-regions over an eleven-year period, I am able to estimate the 
causal  impact  of  the  flu  shot  campaign  on  work  absences,  hospitalization  and  other  health 
outcomes. Estimates of the program effect imply that the sustained 9 percentage point relative 
increase in vaccination for Ontario post 2001 prevented 2 deaths per 100,000 people annually and 
led to a 67 percent decrease in overall flu admissions when the clinical match of the flu shot is 
perfect  (a  perfect  match  occurs  in  1  out  of  every  2.2  seasons).  The  near  elimination  of  flu 
admissions corresponds to predictions from a standard structural model of flu dynamics. Here, a 
vaccination  rate  above  31  percent  combined  with  a  perfectly  matched  vaccine  is  predicted  to 
prevent a flu epidemic.
4 The Ontario campaign achieved a vaccination rate above 31 percent while 
average vaccination in other provinces remained below. This corroborates the large effects found 
for flu admissions, which were nearly eliminated in perfect match flu shot years, and may shed 
light on the possible benefits of a flu vaccine specifically matched to the H1N1/09 strain of flu.  
I  also  find  that  the  flu  campaign  has  implications  for  labor  force  productivity.  Using 
monthly labor force survey data, I find that during the flu season the program leads to a 22 percent 
decrease in worker illness absence in a perfect match year. These results are further supported by 
evidence for other measures of illness. There is a 34 percent decline in the weekly surveillance rate 
of  lab  tested  flu,  a  30  percent  decline  in  bi-weekly  bed  illness  and  a  13  percent  decline  in 
                                                 
3 An advertising effect is interesting in its own right. However, if decreases in illness are driven from program advertising about 
infectious disease and not from flu shot delivery this has alternative implications for program design.  
4 In effect, by reducing the size of the susceptible population, vaccination reduces the average number of infections caused by an 
infected individual. Given parameters regarding the infectiousness of flu; average infections will fall below the rate of one 
(meaning, an infection less than replaces itself) at a vaccination rate greater than 31 percent.   4 
consumption of over-the-counter cold and flu medications.  
  The second stage of this paper focuses on estimating the effects for adults over the age of 
65. The flu shot is covered for older adults in all provinces since the early 1990s. Hence, coverage 
status for this group is unchanged as a result of the Ontario campaign. This is reflected in relative 
vaccination patterns. For older adults, there is no difference in vaccination rates post program in 
Ontario when compared with other provinces. If we are willing to assume that this age group is 
unaffected by the vaccination of others, then within this age group, there should be little additional 
gain for Ontario in high match versus low match years. If there is a difference in the relative gain 
for older adults, such that illness declines more so in Ontario in perfect match years, it indicates 
that this age group was positively affected by relative increases in the vaccination of others. For 
older adults, I examine hospitalizations, bed illness, and cold/flu medications and find significant 
reductions in these illness outcomes. This suggests that there are external effects for this older 
group due to the increased vaccination of younger groups.  
  Relative  to  program  costs,  the  implied  aggregate  benefits  of  the  Ontario  campaign, 
including spillover benefits to older adults, are substantial. Given the average cost of respiratory 
hospitalizations and the average wage, the impact of the flu shot campaign translates into best-case 
scenario cost savings of $174 million in a high match season. The expected cost savings (average 
cost savings multiplied by the expected match rate) yields a program benefit of $124 million. 
Program costs, on the other hand, are much less. The campaign delivers on average 6 million more 
vaccinations per season. This represents $19 million in additional administration costs and an extra 
$14 million in vaccine costs, totaling $33 million annually. 
  Estimates from this study are robust to using several definitions of the clinical match rate: a 
dichotomous definition (match versus no match), a continuous measure scaled by the proportion of 
unmatched flu strains in each province and year, or the log of this continuous measure to allow for 
nonlinearities in the effect of the match. It is not possible to completely rule out concurrent events 
that may be correlated with the effect of the flu shot match in Ontario post 2001 but such events 
are unlikely. For instance, a coinciding policy that was able to directly affect general immunity to 
disease  could  explain  differences  for  Ontario  in  high  match  versus  low  match  flu  shot  years. 
However, this is an unlikely explanation since health policies are typically (both before and after 
2001) directed to treatment and not preventative care. Furthermore, such a policy, being related to 
general immunity, would have a general effect on health. However, I find no differences for other   5 
types of hospitalizations besides those that involve flu or flu complications. Moreover, I find no 
effects on flu related illness measures in periods other than during high flu season. 
  This paper makes a number of contributions: (1) by using exogenous variation in the match 
of the flu shot to the flu and the novel immunization campaign in Ontario, I am able to estimate the 
causal impact of a program providing vaccines to all age groups, (2) by using a comprehensive 
dataset on all acute hospitalizations in Canada spanning a number of seasons across numerous 
well-defined geographical areas, I am able to use flexible specifications that include month, season 
and  city-region  fixed  effects,  analyze  hospitalizations  where  flu  was  either  the  primary  or 
secondary diagnosis, and analyze other types of diseases to rule out misspecification, (3) I am able 
to provide evidence of positive externality effects for the elderly from the vaccination of children 
and younger adults, and (4) by using labor force survey data, I am able to provide the first large-
scale evidence of the effect of vaccination on worker productivity by looking at the impact on 
worker absenteeism.  
  This paper is organized as follows; Section 2 provides background information on the flu 
virus and vaccine, vaccination recommendations,  provincial vaccination programs, and outlines a 
direction for the empirical approach. Section 3 outlines the identification strategy and Section 4 
describes the data and presents descriptive statistics. Section 5 presents results. First, I present a 
main  set  of  results  for  flu,  pneumonia  and  worker  absenteeism.  Second,  I  explore  effects  for 
different  age  groups.  Lastly,  I  provide  further  evidence  on  bi-weekly  bed  illness,  monthly 
consumption of over-the-counter cold and flu medicines, laboratory confirmed flu rates and other 
hospital admissions for diseases such as heart disease, cancer and chronic respiratory disease. 
Section 6 provides interpretation and Section 7 concludes. 
 
2 Background 
2.1 The Flu  
Influenza (or flu) is a common respiratory virus that is contagious through droplet spread.
5 
The virus begins circulating in the fall and winter months and is usually the predominant cause of 
serious respiratory disease during this time (WHO 2003). In the U.S., the flu is estimated to be 
responsible for 100 million days of bed disability, 75 million days of work absenteeism, and 22 
                                                 
5 Transmission occurs through spread of respiratory droplets from an infected source to the eyes, nose or mouth of a susceptible 
person. Further summary information on influenza and vaccination is available from the U.S. Center for Disease Control and 
Prevention (http://www.cdc.gov/flu/about/disease/index.htm) or the Canadian Immunization Guide published by the Public Health 
Agency of Canada (http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php)   6 
million health care provider visits per year for those aged 18 to 64 (Benson, et al. 1998). For high-
risk  groups,  flu  and  its  related  complications  account  for  between  100,000  to  300,000 
hospitalizations and between 20,000 to 40,000 deaths during each flu season (Thompson, et al. 
2003, 2004). Research has also linked flu infection with added long-term effects. For instance, 
children  in  utero  during  the  1918  H1N1  flu  pandemic  displayed  increased  rates  of  physical 
disability and decreases in income and educational attainment in later life (Almond 2006).  
Recovery from the acute effects of flu occurs within three to fourteen days. In some cases, 
the flu can lead to death, particularly if infection develops into pneumonia or is coupled with other 
complications  such  as  asthma,  heart  disease  or  other  conditions  associated  with 
immunosuppression  (PHAC  2007).  Infection  risk  begins  prior  to  the  onset  of  symptoms  and 
continues for a number of days after recovery (CDC 2008). In addition, the virus can stay virulent 
on surfaces for a varying length of time. At body temperature, the virus is usually inactivated in 
less than a week whereas in cool dry temperatures the virus can last considerably longer (Zhang, et 
al. 2006). This is, in part, the reason why seasonal epidemics appear during winter months (WHO 
2006). 
  There are many strains of the flu virus that are genetically differentiated or typed on the 
basis of surface antigens and the genetic structure of the virus is constantly changing over time 
through  point  mutations.  This  evolution  results  in  antigenic  drift  and  depending  on  antigenic 
changes, the cross-immunity to the new strain that was conferred by the previously circulating 
virus can be minimal (PHAC 2007).
6 
 
2.2 Vaccination  
  The flu shot was developed in the 1940s but was only more widely used following early 
1990s initiatives by public health organizations emphasizing the shot for selected high-risk groups 
(Fedson et al. 1995). The flu shot provides protection against the flu by triggering an antibody 
producing immune response to targeted strains of flu. Because of this, protection depends on the 
match of the vaccine cocktail to circulating strains of flu. For instance, in a systematic review of 
evidence from randomized control trials, Jefferson et al. (2007) note that lower efficacy rates are 
estimated  in  studies  whose  timing  corresponds  to  seasons  where  vaccine  content  is  not  well 
matched to circulating strains.  
                                                 
6 This is particularly the case with the H1N1/09 strain, which has been described as an unusual re-assortment of existing H1N1 
strains. Here, H1 represents the haemagglutinin antigen type and N1 represents the neuraminidase antigen type of Influenza A.   7 
Vaccine protection usually begins within two weeks of receipt of the immunization and is 
sustained for six months or longer; however, if immune response is compromised (as is the case 
for those in low health or with weaker immune systems), then antibody levels may be below what 
is needed for full or sustained protection (CDC 2008). For instance, Jefferson et al. (2007) find a 
vaccine efficacy rate of 80 percent in healthy adults. Meanwhile, the results for children and older 
ages are lower: systematic review of the evidence yields an efficacy of 62 percent for children 
under  18  (Manzoli,  et  al.  2007)  and  an  efficacy  of  58  percent  for  adults  over  the  age  of  65 
(Govaert, et al. 1994).   
It is due to the constant genetic change in flu and the relevance of match to efficacy, that 
the flu vaccine is reformulated each year to account for changes in the antigenic composition of flu 
strains. The World Health Organization (WHO) closely monitors circulating flu viruses across the 
world and in early spring writes the annual vaccine recipe. The vaccine is constructed to target the 
most virulent strains in circulation and includes two subtypes of flu A (H3N2 and H1N1) and one 
flu B virus. Usually, one or two of the three virus strains in the vaccine are changed each year and 
the prescription is identical across the North American continent (WHO 2006).  
Each year. Health Canada licenses the newly formulated inactivated flu vaccine for use.
7 
Once  licensed,  the  Government  of  Canada,  through  Public  Works  and  Government  Services 
Canada (PWGSC), purchases flu vaccines on behalf of the provinces and territories for distribution 
in late October early November.
8 The turn around period from the yearly WHO recommendation 
to  availability  of  the  vaccine  is  approximately  6  to  8  months  depending  on  manufacturing 
conditions (Health Canada 2007).  
 
2.3 Vaccination Programs in Canada 
  Provincial governments make flu vaccine available at public health clinics and doctor's 
offices in accordance with provincial influenza immunization programs.
9 Beginning in the early 
1990s, all provinces developed vaccine programs covering the cost of vaccination for specific 
groups. The standard covered group included recipients less than 24 months or 65 years and older, 
                                                 
7 To date, Health Canada has only licensed inactivated vaccines (containing killed virus strains) instead of live attenuated vaccines 
(containing weakened flu). It is thought that live attenuated vaccines are associated with adverse reactions that may not result from 
inactivated vaccines. However, since the virus has been killed, the immune response to an inactivated vaccine may be less than that 
of a live-attenuated vaccine.   
8  Administrative  data  from  Ontario  OHIP  physician  billings  show  that  the  majority  of  yearly  vaccination  takes  place  before 
December (Kwong and Manuel 2007). Similarly, survey data from the U.S. (the NPHS 2008) show that 91 percent of vaccinated 
respondents had received the current flu vaccine by December.  
9 Government approved flu vaccines are also available through private market contracts.   8 
health care support staff, residents in care homes, and those with specific chronic conditions (Gao 
2004).
10 Aside from minor changes to provincial programs, immunization targeting remained the 
same across all provinces with the exception of Ontario.
11 The provinces have otherwise similar 
health care systems, per capita health expenditures, physicians numbers and health resources (IHE 
2006, 2008). 
In  July  of  2000,  the  Government  of  Ontario  announced  the  extension  of  vaccination 
coverage  to  all  residents  of  the  province  through  what  it  called  the  Universal  Influenza 
Immunization Campaign (UIIC). The campaign was only one part of a larger ten-point plan to 
reduce emergency room wait times (Kurji 2004). The stated objective of the program was to ease 
pressure  on  health  facilities  and  providers,  in  particular  emergency  rooms,  by  decreasing  the 
impact of influenza during the flu season (MOHLC 2000). Even though the program targeted, by 
default, healthy prime age individuals, it was expected that this would afford protection for high-
risk  groups  with  already  high  rates  of  vaccination  through  an  externality  effect.  Secondary 
objectives of the program were to decrease the economic impact of the flu during flu season and 
also to build infrastructure for delivery of flu or other vaccines in the event of a pandemic (Kurji 
2004). In its first year, the program cost $31 million with 6 million vaccines administered (up from 
2.1 million in the previous season) (Kurji 2004). The total program cost is a small portion of the 
overall health care budget of more than $30 billion annually and program funding is independent 
of hospital and physician budgets, which are determined separately through funding formulas and 
negotiations with the Ontario Medical Association. 
 
2.4 Vaccination Recommendations and the Universal Influenza Immunization Campaign 
The  impact  of  flu  vaccination  on  respiratory  infection  and  mortality  is  a  key  issue  in 
developing recommendations for the use of vaccines, and is valuable information for public health 
agencies that are unwilling to invest in programs that do not yield adequate benefits. Previous 
estimates of the impact of vaccination did not support policies of immunizing younger individuals 
outside of certain high-risk groups. For instance, based on meta-analysis of several randomized 
evaluations, Demicheli (2001) claims that the benefits to vaccinating healthy adults are small and 
                                                 
10 Covered conditions include cardiac or pulmonary disease, asthma, diabetes, renal disease, liver disease, anaemia, HIV, and 
cancer. 
11 Quebec and New Brunswick made more recent changes to the coverage status of older adults. Quebec added 60 to 65 year olds to 
the standard covered group in 2001 and New Brunswick formally added coverage for ages 65 or older in 2002 (CPA 2007, 2003). 
The change in New Brunswick had no measurable effect on vaccination and due to data constraints in Quebec, this province cannot 
be included in the analysis (hospitals in Quebec did not submit to the national database for the full sample period).   9 
“at odds with the conclusions reported in previous meta-analysis of evidence for the effect of 
immunization on elderly people, which showed greater clinical effectiveness, thus supporting the 
present worldwide policy of vaccinating only elderly people and other high-risk groups.”  Further 
to this, more recent surveys of cost benefit analysis indicate that evidence on the efficiency of 
vaccinating healthy adults or children continues to be mixed with no uniform prescription on the 
validity of recommending vaccination for these groups (Nichol 2003, 2008).  
Yet evidence from these studies suffers several shortcomings that may lead to incorrect 
conclusions as to the benefits of vaccination, particularly as it applies to a broad based policy on 
immunization. First, study design of existing randomized evaluations is typically defined over one 
flu season for a particular group (workers at a firm, patients of a clinic, residents of a nursing 
home,  et  cetera).  This  makes  it  difficult  to  compare  results  across  studies  and  has  lead  to 
inconclusive  evidence  on  the  impact  of  vaccination  and  the  associated  benefits  for  different 
groups. Furthermore, from the diversity in estimates and the specificity of the chosen sample, it is 
then unclear how these results extrapolate to a generalized population. Finally, since these studies 
typically isolate only one flu season, they cannot adequately account for the role of the flu vaccine 
match, which impacts the estimated benefits of vaccination systematically.   
A second, possibly more important issue is that previous estimates are likely contaminated 
by treatment spillovers from the treated group to the control group. Specifically, these studies 
often  randomize  vaccination  within  a  chosen  sample  and  compare  outcomes  of  treated  and 
untreated groups. However, such methods fail to deal with benefits for the untreated group that 
accrue from vaccination of the treated, which may be large if the sample is chosen from, for 
instance,  a  specific  locale  or  workplace.  This  difficulty  has  been  shown  in  other  contexts 
(Philipson 2000b; Miguel and Kremer 2004). Miguel and Kremer (2004) illustrate this concern in 
their seminal study of worms and deworming interventions. In their study, the authors evaluate a 
mass  deworming  program  in  Kenya  that  randomly  phased  in  deworming  interventions  at  the 
school level rather than within school (at the student level). Earlier studies based on within school 
randomization  had  found  mixed  evidence  of  the  effect  of  deworming  treatment  on  schooling 
outcomes but had failed to deal with the possibility of treatment spillovers. Because randomization 
took place at the school level in the Kenyan program, Miguel and Kremer are able to estimate the 
overall effect of the deworming intervention that is not contaminated by treatment spillovers. In 
contrast to previous evidence, the authors find that the deworming program had larger effects on   10 
schooling  outcomes  than  previously  estimated  and,  notably,  the  program  reduced  school 
absenteeism by 25 percent in treatment schools. Further to this, by taking advantage of variation in 
the local density of treatment schools nearby, they also find evidence of cross-school treatment 
externalities, providing substantive evidence that children do benefit from treatment spillovers in 
the context of deworming interventions.  
From the perspective of flu vaccination, if such externalities exist, evidence that fails to 
account for such spillovers will incorrectly estimate the effect of the vaccine. This is particularly a 
problem when establishing evidence based public health recommendations because the true impact 
of vaccination will always be understated if the untreated group experiences a decrease in illness 
due to treatment externalities and thus, estimates would cause one to conclude that vaccination is 
less  beneficial  than  its  true  measure.  It  may  be  on  these  grounds  that  other  jurisdictions  had 
developed recommendations that were far more limited in scope than the Ontario program. The 
program, itself, was the first in North America to recommend and provide the flu shot to all groups 
and,  in  fact,  a  main  criticism  of  the  campaign  was  that  it  was  not  evidence  based:  previous 
estimates did not support a policy of mass immunization. 
Yet by its nature, the Ontario program offers a good experiment to address whether such a 
policy is worthwhile. While previous evidence was only able to evaluate immunization for specific 
groups in specific contexts, evaluation of the Ontario campaign can assess the benefits of a broad 
public  health  campaign.  Further,  instead of  comparing  vaccinated  and  unvaccinated  groups  in 
Ontario, patterns in Ontario can be compared to patterns in provinces whose populations have 
similar  baseline  vaccination  behaviors  but  that  experienced  no  change  in  immunization 
programming. By comparing city-regions in Ontario to city-regions outside Ontario, estimates of 
the  total  impact  will  be  free  of  the  treatment  externalities  that  would  accrue  post-program  to 
unvaccinated groups in Ontario. 
One remaining issue in detecting the true impact of the universal campaign is a careful 
accounting of differential trends among comparison provinces. For instance, Groll and Thompson 
(2006) find that there is a small relative increase in surveillance counts of laboratory confirmed flu 
for Ontario compared to other provinces at the introduction of the universal program. However, 
the authors fail to account for trends in the number of tests performed. Since surveillance testing 
increased  more  so  post-program  in  Ontario,  this  would  likely  translate  into  higher  counts  of 
positive tests. Existence of such observed or unobserved differential trends can yield incorrect   11 
estimates  of  the  program  impact  and  analyses  that  do  not  account  for  these  differences  may 
erroneously attribute them to the introduction of the campaign.  For example, despite the fact that 
Kwong et al. (2008) find relative decreases in death, hospitalization, and emergency room visits at 
the  introduction  of  the  campaign,  there  is  no  way  to  know  if  these  decreases  are  free  from 
alternative explanations. 
Similar  problems  arise  in  evaluating  other  public  health  interventions.  Consider,  for 
example, the Rockefeller Sanitary Commission eradication campaign waged against hookworm in 
the  American  South.  Simple  comparison  of  outcomes  before  and  after  the  campaign  cannot 
disentangle  the  effect  of  hookworm  eradication  from  alternative  explanations  for  trends  in 
outcomes.  Bleakley  (2007)  addresses  this  problem  by  comparing  the  pre-post  impact  of 
eradication for areas with higher levels of baseline hookworm (implying greater benefits from 
eradication)  to  areas  with  lower  baseline  levels  of  hookworm.  Since  pretreatment  levels  of 
hookworm were, arguably, exogenous (the campaign was motivated by innovations in knowledge 
regarding  the  presence  of  the  disease  itself),  interpretation  of  the  effect  on  child  schooling 
outcomes is free of endogeneity problems that would be associated with alternative factors co-
determining both hookworm infection levels and future growth. 
To account for similar concerns in comparing outcomes among provinces before and after 
the vaccination campaign in Ontario, I compare the relative impact of the program in Ontario for 
flu seasons with higher vaccine match rates (implying greater benefits to the program) to seasons 
with lower vaccine match rates. Since mismatches are determined by random genetic mutation of 
flu  strains  as  they  relate  to  yearly  vaccine  content  choices,  mismatches  can  be  thought  of  as 
exogenous.  For  example,  I  argue  that  mismatches  are  not  related,  for  better  or  for  worse,  to 
program  adoption  in  Ontario.  In  fact,  vaccine  content  is  identical  across  North  America; 
preapproved by Health Canada across all provinces; and held fixed over each yearly flu season.  
 
3 Identification Strategy 
  The purpose of the empirical work is to study the links between vaccination and health by 
identifying the impact, attributable to vaccination, of a broad scope immunization campaign. I start 
with an underlying model linking vaccination to health (broadly defined) with linear effects of 
vaccination: 
  
hijt = m jtvijt +  m jtv  (i) jt + Xijt + ijt                                                     (1)   12 
Here, hijt is a health measure for individual i residing in region j at time t, Xijt is some vector of 
individual controls, and  ijt is an individual error term. The coefficient    is meant to capture the 
individual  effect  of  vaccination  (denoted  vijt)  from  person  i's  vaccination  decision  while  the 
coefficient,  , is meant to capture the effect of average vaccination excluding person i (denoted 
  
v  (i) jt). In other words, it is the external effect of vaccination on the illness of person i arising from 
the vaccination behavior of others.  
  It is often the case that individual level data on vaccination and illness are unavailable. In 
this setting, the total effect of vaccination can be obtained from the aggregated model in (2): 
  
h jt =  m jtv jt + X jt +  jt                                                            (2) 
where 
  
h jt is average health in region j at time t and where both own and external effects of 
vaccination are included in  , the total effect of changes in average vaccination in region j at time 
t.
12 If vaccination prevents illness, then   is assumed to be positive. 
  Estimation of   presents a number of potential challenges. For instance, if lower baseline 
levels  of  average  health  are  associated  with  higher  vaccination  levels,  then  this  unobservable 
association will mitigate the relationship between vaccination and health and would bias estimates 
of the effect of vaccination downward. The data show that this is a probable concern. For instance, 
comparing  vaccinated  and  unvaccinated  groups,  the  data  show  a  counterintuitive  connection 
between  vaccination  and  health  during  the  summer  season  where  the  vaccine  is  unlikely  to 
causally impact health. Specifically, in the summer months where flu is not in circulation, the rate 
of  recent  short-term  bed  illness  for  vaccinated  individuals  is  16  percent  higher  than  that  of 
unvaccinated  individuals.  This  finding  demonstrates  selection  into  vaccination  that  is  likely 
generated from heterogeneity in the return to immunization. Those in poorer health or with higher 
infection  probabilities  have  higher  returns  to  immunization  and  thus  may  be  more  likely  to 
vaccinate. However, they are also more likely to experience negative health shocks, which may 
drive part of the relationship observed between health and vaccination.  
  Additionally, there may be other sources of selection that contribute to year by region 
variation in vaccination rates. For example, variation in incidence of other infectious diseases 
                                                 
12 Here,   is a function of the individual and external effects of vaccination and it enters linearly into the model in (1). The 
implications of decreasing returns to vaccination are discussed below and specifications capturing non-linearities in the response to 
vaccination and match are also explored in the reduced form counterpart to this model and are available upon request.   13 
(colds, other respiratory viruses, et cetera) may be correlated with selection into vaccination and 
are also associated with health outcomes. In this case, the positive association between vaccination 
and health would be mitigated by this correlated effect. Furthermore, vaccination, itself, may be 
associated with other behaviors that affect health. For instance, hand washing or other prevention 
methods may increase after receiving the vaccine. If, for instance, a higher vaccination rate is 
associated with increased exposure to prevention information and increased prevention behaviors, 
then rates of illness may be lower regardless of receipt of the shot.  
  In the present study, there are several factors that contribute to identification of the effect 
of the broad scope Ontario immunization campaign. The first factor is time-region variation in a 
campaign that delivered vaccines free of charge to all age groups. The initiation of the campaign 
was unlikely motivated by higher levels of flu in Ontario: evidence indicates that, if anything, 
Ontario  had  marginally  lower  baseline  surveillance  rates  of  flu  and  flu  hospitalizations.  The 
second factor is that in different years and across provinces, there are different degrees of match 
between  the  flu  shot  and  the  flu.  Furthermore,  these  mismatches  are  determined  by  random 
mutations in flu as they relate to yearly vaccine content, which is predetermined and fixed across 
North America and over each year. This means that, unknown to the recipient at the time of 
vaccination, the flu shot may offer a high degree of protection or it may offer a marginal degree of 
protection. Accordingly, areas with higher levels of vaccination will experience greater benefits if 
the flu shot is a good match and smaller benefits when it is not. These factors combined, suggest 
the following reduced form model: 
  
yajt =  1(Postt *m jt)+  2(Postt *Ont j)+  3(Ont j *m jt)+  4(Postt *Ont j *m jt)+ X jt + µajt         (3) 
where yajt is an illness outcome for age group a in region j at time t and Xjt is a vector of controls 
which may include, for example, surveillance counts of other respiratory disease to capture other 
possible changes in compensatory behavior; expenditures on health resources such as hospitals, 
physicians, and capital investments; the match rate in levels; and age, region, season and month 
fixed effects. The variable uajt is an error term with allowance for correlation at the province 
cluster level.
13  
  Inclusion of region effects captures fixed features among regions and will account for 
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logit or probit estimators. These results are not reported here but are available upon request.   14 
unobservable region differences that are common across all seasons and all age groups. Similarly, 
by controlling for season and age effects, the model in (3) accounts for any fixed differences 
among  seasons  (across  age  and  provinces)  and  age  groups  (across  season  and  province). 
Remaining variation in illness is explained by factors that vary across age, region and season and 
will  be  determined  by  any  number  of  sources.  To  detect  that  which  is  attributable  to  the 
immunization campaign and is due to changes in vaccination, I control for other unobservable 
differences occurring in Ontario post program and I also take into account that the match rate, in 
addition to impacting illness on its own, may have a differential impact among all provinces post 
program  and  a  differential  baseline  impact  in  Ontario.  These  factors  are  captured  by  the 
coefficients  1 to  3. Explicitly,  1 captures differences in the effect of the vaccine match post 
2000 and hence controls for gains in the effect of the match that are common to all provinces; the 
coefficient  2  captures unobservable differences in illness in Ontario versus other provinces post 
program; and the coefficient  3  controls for baseline differences in the gain from the match that is 
different in Ontario versus the other provinces. After controlling for these factors and the factors in 
Xjt, the remaining variation in illness is captured by  4 , which summarizes the difference in the 
post program effect of the match for Ontario and captures the gain in illness prevention in good 
match  years  that  is  explained  by  the  increase  in  vaccination  attributable  to  the  immunization 
campaign. 
  The identification strategy employed in (3) rests on the notion that the match rate directly 
affects the efficacy of vaccination. Aside from laboratory analysis on this relationship, the patterns 
observed in flu surveillance and previous literature on vaccination efficacy reveals that this is a 
reasonable  conjecture.  For  instance,  in  a  systematic  review  of  randomized  control  studies  for 
healthy  adults,  Jefferson,  et  al.  (2007)  find  that  the  efficacy  of  vaccination  for  laboratory 
confirmed flu was 80 percent for studies performed in good match years while it was 50 percent in 
studies where there was a vaccine mismatch. Although these results should be interpreted with a 
degree of caution: there is considerable variability in study design and sample characteristics, it 
does indicate a basis for the argument that the match can impact the efficacy of the flu shot. 
  Since the research design is Equation (3) is not experimental, results should be interpreted 
within the context of the program studied. Specifically, since there is likely heterogeneity among 
individuals who received the shot after the program versus those that did not, the results are an 
average effect specific to this group of takers. On the other hand, since these types of selection   15 
issues are likely to take place in a policy setting, this information may be of more use to policy 
makers than that which is based on random assignment of vaccine. This will be the case when 
broad policies replicating random assignment or strict mandated immunization are more difficult 
to implement than polices involving price incentives or promotion of the vaccine. A second caveat 
remains due to heterogeneity in the externality effect of such a program. Since there may be a 
distinction in the externality effect associated with different levels of vaccination, the effect found 
here is specific to these changes in vaccination relative to baseline levels. The effect found in this 
study  will  be  smaller  than  the  expected  effect  for  jurisdictions  with  lower  baseline  levels  of 
vaccination (assuming decreasing returns to vaccination). 
  This methodology can be modified to allow for differences in initial vaccination levels. 
This would be a possible way to investigate whether these results also reflect decreasing returns to 
vaccination that operate through differences in baseline average vaccination. Unfortunately, there 
is little variation in initial vaccination rates for regions in Ontario and regions elsewhere, making it 
difficult to examine this hypothesis. Alternatively, it also rules out this argument as a possible 
explanation for the effect that I find; the return to the immunization program, as it depends on 
initial vaccination levels, is not generated though regional differences in the returns to vaccination.  
 
4 Data and Descriptive Statistics 
The  empirical  analysis  draws  together  information  on  health  and  economic  outcomes, 
vaccination status, and the seasonal vaccine match. Table I contains information on the source and 
sample period of each data set.  
 
4.1 Vaccination 
I  use  master  file  health  survey  data  from  Statistics  Canada  in  order  to  document  the 
changes in flu vaccination and to provide supporting evidence of the impact of the immunization 
campaign on short-term health outcomes (bi-weekly bed illness and over the counter cold and flu 
medicines). There are four health surveys that contain questions relevant to flu vaccination: the 
National Population Health Survey (NPHS), Cycle 2 1996/1997 and the Canadian Community 
Health Survey (CCHS), Cycles 1.1 (2000/2001), 2.1 (2003) and 3.1 (2005).
14 These surveys are 
national, population-based surveys conducted on persons 12 years of age or older. In addition to 
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collecting  demographic,  socioeconomic  and  health  information,  these  surveys  also  collect 
information on current and previous vaccination status. In each survey, the respondent is asked: 
“Have you ever had a flu shot?” and if the answer is affirmative, respondents are asked a follow up 
question: “When was your last flu shot?” Following the definition used by the Public Health 
Agency of Canada (PHAC) and the Center for Disease Control and Prevention (CDC), I define the 
flu season year to be the year starting in October and continuing to September of the following 
year. This is based on the timing of vaccination delivery in early fall and the seasonal pattern of flu 
circulation. Using this definition, I can determine coverage rates for each flu-season year by using 
the time of survey and current vaccination status for survey respondents.  
Figure I shows vaccination rates for regions in and outside Ontario by age group over time. 
The figure shows increases in vaccination from 1996 to 2006 for all age groups and also shows 
that the young have lower vaccination rates than the old over the same time period. The figure also 
indicates that, while baseline vaccination rates for the young are not substantially different for 
regions  in  and  outside  Ontario,  there  are  significant  gains  in  vaccination  for  Ontario  at  the 
introduction of the program. Beginning in the 2000/01flu season and continuing to 2005/06, there 
is a 10 percent relative shift upward in vaccination for the young in Ontario. The same is not 
evident in the older age group. While the vaccination rate for ages 65 and older is greater for 
Ontario over the entire sample period, there is no relative change in vaccination at the introduction 
of the program.  
To explore differences in program impact among sub groups, Table II gives a summary of 
vaccination rates pre and post October 2000. The table shows that, overall, vaccination rates have 
increased for all regions in the post period relative to previous rates.  For instance, post program, 
there is a 20.8 percentage point increase in the vaccination rate for regions in Ontario and a 12.2 
percentage  point  increase  in  regions  outside  Ontario,  yielding  a  8.7  percentage  point  relative 
increase  in  Ontario  following  the  program.  The  relative  gain  in  vaccination  for  Ontario  post 
program is due to an increase of 10.8 percentage points for those under 65. Ages 65 or greater 
(who were not targeted by the coverage changes) have a small and insignificant relative increase 
of .4 percentage points. It is clear from these data, that the impact of the program is centered on the 
age group that was targeted by program incentives. 
The  remainder  of  Table  II  presents  summary  statistics  for  ages  under  65  by  selected 
characteristic. Baseline vaccination patterns for all provinces fall in line with previous research on   17 
the determinants of vaccination (Mullahy 1999): females are more likely to vaccinate than males, 
vaccination is increasing in education (with the exception of those without secondary education), 
and  is  decreasing  in  income  and  time  spent  working.  Underlying  health  may  play  a  part  in 
explaining  these  patterns  as  there  are  likely  correlations  between  these  factors  and  health 
characteristics. Meanwhile, health characteristics are also a likely determinant of vaccination. This 
is evident in the table, which shows substantial differences in baseline vaccination for different 
levels  of  self-rated  health.  These  differences  may  reflect  diversity  in  the  expected  cost  of  flu 
infection relative to costs of immunization: those who state excellent or very good health likely 
have lower expected costs of infection, while those with fair or poor health are likely have higher 
expected costs of infection. In the same vein, the data show that chronic conditions covered under 
provincial  vaccination  programs  are  associated  with  substantially  higher  baseline  levels  of 
vaccination.  
Focusing on patterns pre-post, the relative increase in vaccination for regions in Ontario 
versus regions outside Ontario is similar across the sub groups indicated. The largest increases, in 
both absolute and relative terms, are among those not in the labor force (possibly reflecting smaller 
time costs of vaccination) and among those with lower income. The relative increase in Ontario 
post program is of similar magnitude regardless of having a covered chronic condition, and self-
rated  health  status  does  not  appear  to  be  related  to  vaccination  uptake  pre-post  program.  In 
Ontario, there are increases of approximately 20 percentage points for all rankings of self rated 
health and relative to other provinces this reflects a 10 percentage point increase.
15  
 
4.2 Health Outcomes 
Data on flu infections are obtained from surveillance counts of laboratory confirmed flu. 
The PHAC collects these data through its respiratory surveillance program. This program collects 
disease tests on a weekly basis from appointed sentinel physicians in a defined surveillance region 
(usually one per census division). The collected tests are sent to laboratories to be assessed for flu 
or other respiratory diseases. In the flu off-season, sentinels are still encouraged to collect tests. I 
use these data for two purposes; the first is to describe the impact of the coverage changes in 
Ontario on the rate of laboratory confirmed flu and the second is to define the period throughout 
                                                 
15 Estimates of the relative increase in vaccination for each of the seven city-regions across Ontario obtained from regression 
analysis controlling for factors such as demographic, economic and health characteristics are consistent with results reported here 
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the year where flu is circulating. I use the flu season period as a conditioning variable for other 
illness outcomes such as hospitalizations and work absenteeism and I define it as the contained set 
of weeks starting from the first week the number of positive tests is greater than 5 percent of the 
season total until the last week it falls below 5 percent.
16 These data are presented graphically in 
Figure II. Panel B shows the laboratory confirmed flu rate (percent of collected tests that are 
positive for flu) and indicates the flu season period of each year. As a matter of construction, there 
will be limited laboratory flu during off-season. The same is not necessarily true for other illness 
measures such as hospitalizations and illness work absences, which may vary according to other 
factors related to health. However, to the extent that laboratory flu is a good measure of whether 
flu is circulating, we should expect that the program impact on health and productivity measures 
should be largest during the flu season (as it is defined here) and minimal during off-season. To 
explore this, I present results for both periods: off-season and flu-season. Further, I break the flu 
season into the period from the season start to peak and the period at season end in order to 
compare estimates among time periods where there is more or less information about the size of 
the yearly epidemic. It is worth pointing out that these periods do not always occur at the same 
time each year: there is variation in the timing of the epidemic. In order to take account of, for 
example, a “December effect” that systematically impacts illness during the month of December, I 
control for month effects in the empirical work.  
Panel A of Figure II indicates the clinical match rate for each season. The pattern between 
match and the incidence of flu is apparent: a mismatch in the vaccine results in a more severe flu 
epidemic  as  measured  by  surveillance  testing.  To  define  the  clinical  match  rate,  I  use  strain 
isolation data from the PHAC along with reports on the cross-immunity of the yearly vaccine. I 
identify all flu strains observed by the PHAC as matched or not matched to the yearly vaccine. 
Reports on strain match are published each year in the Canadian Communicable Disease Report 
(CCDR). Additionally, I compare these findings with that of the U.S. Center of Disease Control 
and the vaccine recipe from the World Health Organization and find that they correspond. In order 
to get a measure of the match rate, I use data from the PHAC sample of strain isolated flu tests. 
During  each  flu  season,  the  PHAC  takes  a  sample  of  positive  flu  tests  in  each  province  and 
identifies individual flu strains. In the sample of tests, each test is categorized based on strain type, 
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the season. In all subsequent analysis, results are reported for all separate periods during the year. An alternative definition of the 
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which can be compared to the yearly CCDR report. The match rate is calculated as the proportion 
of strains in the sample that are a match (i.e. have cross immunity) with the current flu shot. Since 
the match rate is 100 percent for a number of seasons, I also examine a dichotomous definition of 
match that is 0 when there is at least one unmatched strain and 1 when there is not. The results are 
not presented here but are consistent with the results that use the continuous definition of match. 
To  investigate  health  consequences  of  flu  vaccination,  I  use  administrative  data  on 
hospitalizations from the Hospital Morbidity Database (HMDB) holdings of the Canadian Institute 
for Health Information. The HMDB data include complete records of hospital inpatient discharges 
for hospitals in Canada. Hospitals in Quebec and non-Winnipeg Manitoba started submitting to the 
HMDB  after  2001  and  are  consequently  excluded  from  the  analysis.  Each  discharge  abstract 
consists of information on patient age, sex and home postal code as well as detailed medical 
information: date of hospital admittance, whether the admittance is from care facility, date of 
discharge,  discharge  with  death  and  detailed  diagnosis  information.  Each  abstract  records  one 
diagnosis labeled the most responsible diagnosis (MRD) and up to 15 co-diagnoses. Using this 
information, I am able to analyze hospitalizations where flu or pneumonia are listed as the MRD 
diagnosis or listed as one of the other 15 diagnoses. I study both flu and pneumonia diagnoses 
since an incidence of flu may be coded as viral pneumonia, a common complication of the flu. I 
also  discuss  results  for  other  known  complications  of  the  flu  such  as:  heart  disease,  other 
respiratory disease and, as a specification check other hospitalizations that do not contain any 
respiratory diagnosis. 
I  use  diagnosis  counts  from  the  HMDB  to  construct  weekly  hospitalization  rates  for 
regions in Canada and I use the definition of economic regions defined by Statistics Canada. Each 
region is made up of a group of adjacent census divisions and is a standard geographic region 
meant to characterize regional economic activity. I use this definition instead of using census 
metropolitan areas since these regions will capture activity both including and surrounding cities 
and also allow for the entire geography of a province to be captured. Localized activity within 
these city-regions is likely to track patterns of flu transmission and by grouping admissions into 
well-defined regions, I am able to control for fixed regional characteristics such as density and 
other unobservables that impact illness. There are 76 regions in Canada, and for reasons of small 
cell size; I combine northern regions in each province leaving a total of 66 regions. Eight of these 
are dropped due to incomplete data for Quebec and non-Winnipeg Manitoba.  Hospitalizations are   20 
assigned to regions based on patient postal code. For each region, I construct rates for different age 
groups. Population counts for each group, region and year are used in the denominator of the 
weekly rates. 
I  am  also  able  to  observe  admissions  originating  from  care  home  facilities.  With  this 
information, I can calculate flu and pneumonia hospitalization rates for care home residents using 
provincial  resident  counts  obtained  from  the  Residential  Care  Facilities  Survey  conducted  by 
Statistics Canada. From the early 1990s, vaccination has been covered for all residents of care 
facilities  across  all  provinces,  and  vaccination  rates  have  been  high  for  this  population.
17  A 
common argument for vaccinating healthier individuals in contact with care facility residents is 
that residents (with lower health and hence lower immune responses to vaccination) may benefit 
from  the  vaccination  of  contacts  even  if  vaccination  levels  for  this  group  are  already  high.  I 
explore this possibility. 
Flu shots may also have impacts along other dimensions. To investigate the effects for 
labor productivity, I use the Labor Force Survey (LFS). The LFS collects monthly information on 
the labor market and demographic variables for household members 15 years of age and older. 
Demographic characteristics include age, sex, marital status, educational attainment, and family 
characteristics.  Labor  force  characteristics  include  employment  information  such  as  usual  and 
actual hours of work, and hours and reasons absent in a reference week. I examine work absences 
“due to own illness” which do not include, for instance, maternity leave, care of children or elderly 
relatives, and vacations or holidays.  
Summary statistics for hospitalization and illness absences are shown in Table III. In Panel 
A, the data show a visible pattern in health measures over different periods during the flu season. 
For flu, pneumonia and work absences, there are higher rates in the same weeks that that flu 
surveillance rates are highest. Meanwhile, there are no obvious differences across periods of the 
year for non-respiratory admissions.  Rates for flu, pneumonia and work absences are also higher 
in seasons with a mis-match vaccine, while non-respiratory admissions show slightly higher rates 
in match seasons (possible reflecting shifts in resource use).  The statistics show that in Ontario, 
hospital admissions are lower, while work absences are higher. Further, across all regions in the 
post-period,  admissions  decreased,  while  work  absences  rose  (less  so  in  matched  seasons, 
however). There are also differences in underlying individual characteristics across mis-match and 
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match seasons (shown in Panel B). For instance, the average age among individuals admitted to 
hospital for flu and pneumonia is higher in mis-matched years. The same is evident for work 
absences but there is very little difference for non-respiratory admissions. This is likely explained 
by  the  fact  that  immunized  groups  are  more  sensitive  to  changes  in  the  match  rate  than  un-
immunized groups. For instance, since older individuals have higher vaccination rates, they are 
underrepresented relative to younger groups when the match rate is high. 
 
5 Results 
5.1 Main Results 
In this section, I investigate overall changes in health by estimating the reduced form version of 
Equation (2). As indicated by this equation, the relationship between health and the match rate is 
hypothesized to be positive: for a given vaccination rate, the match rate will influence health to the 
extent  that  the  protection  afforded  by  the  vaccine  depends  on  the  quality  of  the  match.  A 
secondary prediction from Equation (2) is that this relationship is increasing in the vaccination 
rate: when the vaccination is higher, a higher proportion of individuals will yield the benefits of a 
good match. 
  To begin investigating the benefits arising from the immunization campaign for worker 
absenteeism,  flu  and  pneumonia  hospitalizations;  I  start  with  a  graphical  depiction  of  the  flu 
hospitalization rate in Figure III, which reveals the patterns hypothesized by (2). The figure shows 
a scatter plot of average flu hospitalizations and vaccine match rates for each flu season-year. The 
linear regression of the average flu hospitalization rate against the match rate is also shown for 
each of four groupings: average flu hospitalizations for city regions outside of Ontario in both the 
pre and post period and average flu hospitalizations for city regions in Ontario, also in the pre and 
post period. As hypothesized in (2), the figure shows that the match has a negative effect on flu 
hospitalizations  in  both  periods  and  over  both  city-region  groupings.  This  is  signified  by  the 
negative slope on the linear prediction in all four groups. The figure also shows a steeper slope for 
the higher vaccination levels occurring in the post period. The difference is only slight for city-
regions  outside  of  Ontario,  but  is  evident  for  city-regions  in  Ontario  (note  that  vaccination 
increased in all provinces but much more so in Ontario). This indicates that, to a much larger 
extent in Ontario, higher vaccine matches now decrease flu hospitalizations more substantially. 
Since this effect operates through variation in the match rate, it corresponds to the substantial   22 
increases in vaccination that followed the immunization campaign. 
It is worth noting the level shift down in the curve that occurs for city-regions outside 
Ontario in the pre versus post period. This shift down indicates that there is post period decreases 
in average admissions that are not explained by variation in the match rate. By comparison, the 
level shift down in Ontario is much smaller and these features outline the possible fallacy in 
simple comparisons of admissions pre-post for Ontario and other provinces. To see this, note that 
downward shifts in the curve indicate that there are other factors besides vaccines that lead to 
decreases in hospital admission rates. Further to this, differences in the magnitude of the shift 
indicate  that  the  impact  of  these  factors  differs  across  region  and  time.  Changes  in  hospital 
resources  may  be  an  example  of  one  contributory  factor  where,  for  instance,  the  number  of 
hospital beds in Ontario remained relatively constant over this period and declined 3 percent in 
other  provinces  (CIHI  2005).
18  Because  of  this,  difference  in  difference  comparisons  among 
provinces will not yield the true effect of vaccination, but will be a combination of the impact of 
this and other correlated factors that change over region and time.  
  It is clear from Figure III that the match has a larger impact on flu admissions after the 
immunization program. Figure IV highlights the program match effect as each seasonal epidemic 
progresses over the year. On the top left side of the figure, the weekly flu hospitalization rate is 
shown for season-years with a mismatch in the vaccine. There is a clear decrease in flu admissions 
post program for all provinces but there are no obvious differences in the magnitude of the flu 
epidemic in Ontario versus the other provinces after program introduction. The top right side of 
the figure shows the flu hospitalization rate for season-years with a perfect match.  In absolute 
terms, the flu rates are much smaller in these seasons relative to those in the plot on the left. This 
reflects the level effect of the match on admissions. The figure also shows decreases in flu post 
program for all provinces, but a more prominent decrease in Ontario. Post October 2000, flu 
admissions were almost eliminated in these season-years. There are similar patterns for pneumonia 
admissions given in the bottom of the figure. Here, the differences between Ontario and the other 
provinces are of a lesser degree.  
Figure III illustrated the importance of controlling for other correlated factors explaining 
hospital admissions and Figure IV highlights differences in seasonal epidemics over region, time 
and match. In order to detect changes in hospitalizations that are causally linked to vaccination, I 
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examine changes in the effect of the match rate: an exogenous determinant of vaccine protection. 
By  comparing  the  impact  of  the  match  on  admissions  over  each  of  the  four  region-period 
groupings,  I  can  control  for  other  factors  that  “shift  the  curves”  over  season  and  region  and 
additionally, I can control for baseline differences in the effect of the match that differ between 
city-regions. I formalize this by estimating the model in (3) and examining the variable of interest, 
Post*Ont*Match. Panel A of Table IV displays the coefficient for Post*Ont*Match in different 
periods during the season. The basic results show a substantial effect on flu admissions throughout 
the flu season. This is after controlling for month, age, city-region, and season fixed effects; the 
level effect of the match; all second level interactions (Post*Match, Post*Ont, and Ont*Match); 
government  health  expenditures  on  hospitals,  physicians,  and  capital  investments;  diagnosis 
specific  coding  classifications  changes  (ICD10  versus  ICD9);  and  the  proportion  of  observed 
strains of each of H1N1, H3N3 and B in each season.  
There is an apparent pattern in the program match effect over the flu season. The largest 
effect occurs in the season start to peak, with a smaller effect during the season end. During the 
season start to peak, the coefficient on Post*Ont*Match is -2.8 per week per 100,000 and the 
effect is -2.4 at the season end. There is little effect in the flu off-season: the point estimate is 
small and insignificant. These results indicate that, while a good flu shot match on its own will 
decrease flu hospitalizations, combined with the flu shot program in Ontario there are significant 
relative decreases that can only be explained by increases in vaccination. The mean match rate is 
71 percent and using the numbers for the season start to peak, results imply that relative to an 
average match, a perfect match leads to a gain for Ontario of 0.9 less hospitalizations per week per 
100,000 after introduction of the immunization campaign. In the season end, there is a gain of 0.7 
less hospitalization per week. In the flu off-season there is no gain for Ontario arising from the 
immunization campaign. 
I also estimate the impact on pneumonia hospitalizations, a frequent complication of the flu 
and a common diagnosis for a flu infection that becomes serious enough for hospital admission. 
These results are in column (3) of Table IV.  Effects for pneumonia are smaller relative to baseline 
levels but significant decreases exist for Ontario when the flu shot is a match. In the season start to 
end  and  relative  to  an  average  match,  a  perfect  match  averts  1.4  hospitalizations  for  Ontario 
compared to other provinces. Again, the magnitude of the effect follows the seasonal pattern of 
flu; the largest effects occur during the flu season with little effect in the off-season. Note that this   24 
is not by construction: except through the effects of the flu and the flu shot itself, there is little 
reason why the patterns we see for pneumonia hospitalizations should systematically follow the 
surveillance patterns of laboratory flu counts.  
Work illness absences also exhibit a seasonal pattern following the seasonal pattern of flu 
surveillance. This is evident in Figure V, which shows average absence rates throughout different 
periods during the year. The top two panels of the figure show absence rates for months occurring 
in five different periods during the flu season: the fall (pre) season, season start, season peak, 
season end, and the summer (post) season. The bottom two panels show flu surveillance rates 
(fraction of tests positive for flu by each week). The peaks in work absences correspond to peaks 
in  laboratory  confirmed  flu  and  are  more  severe  when  there  is  a  mismatch  in  the  vaccine. 
Moreover, despite the evident trend upward in work absences, there are mitigated increases for 
Ontario specific to good match flu shot years along with much more mitigated peaks in flu season 
periods. Column (4) in Table IV confirms these results. In the base specification, good flu shot 
years post-program in Ontario are associated with less work illness. Moreover, this is specific to 
the high flu season periods of the year. This pattern is found when controlling for differences over 
season-years, differences over regions, differences over age groups, differences over months and 
other  controls  (including:  all  base  specification  controls  and  education,  marital  status,  sex, 
occupation and union status). In the season start to peak, there was a 0.5 percentage point decrease 
in worker illness. From a base of 2.7 percent this represents a 19 percent decrease when the flu 
shot  is  a  perfect  match  and  implies  that  relative  to  the  average  match  rate,  a  perfect  match 
decreases worker absences in Ontario by 0.2 percentage points (7 percent relative to base). I also 
explore several non-linear specifications, such as using the log of the match rate or probit/tobit 
models, to investigate diminishing marginal effects of the match. These results, not shown here, 
demonstrate similar patterns.  
To test whether estimates are sensitive to a potential behavioral response to predicting or 
learning the match rate, I present results in Panel B that control for changes in circulation of other 
infectious disease. If individuals can accurately predict or learn the match for each season and 
residents of city-regions in Ontario are even better able or more responsive to these predictions 
after the immunization campaign, then it may bias results. In this case, in a bad match year, 
individuals can potentially compensate through other protective behaviors such as washing hands. 
If Ontario residents are more responsive specific to the introduction of the campaign, then results   25 
will be underestimated. To assess whether this is the case, I use data on surveillance rates of other 
infectious disease collected by the PHAC. The diseases included are respiratory syncytial virus, 
parainfluenza, and adenovirus. These diseases are non-vaccine preventable respiratory viruses that 
are  infectious  through  the  same  manner  as  the  flu  with  similar  symptoms.  If  compensatory 
behavior impacting flu circulation does exist in the manner described, then this behavior will also 
impact circulation of other infectious disease. In order to test this, I control for disease surveillance 
for other infectious disease and compare results to previous estimates. Panel B shows that point 
estimates are somewhat larger (in absolute terms), but the difference is negligible (in magnitude 
and significance). These results support the supposition that individuals are unable to predict and 
adjust behavior according to the match rate to a higher degree after the immunization campaign. 
 
5.2 Impact on Lost Time to Illness 
The immunization program had effects along other dimensions. Table V shows the effects 
for death, wait time in ER before admission, total hospital days and average length of stay. Results 
indicate that there are large effects for death; relative to the average match, a perfect match after 
the immunization campaign delayed 0.04 deaths per week per 100,000 for flu and 0.17 deaths per 
week from pneumonia. This represents a gain of almost 2 fewer deaths per 100,000 per season. 
There are also decreases in time spent waiting in the ER before admittance to acute care, although 
these results are not statistically significant.
19 There is a significant decrease in the number of 
hospital days per 100,000, an effect that is mainly due to fewer hospitalizations: average hospital 
length of stay increased when there was a good match post program in Ontario, although this 
effect is statistically indistinguishable from zero. These results along with the decreases in wait 
time from emergency to admittance may indicate a decreased crowding effect; less hospitalizations 
may mean more resources put towards other hospitalizations. I explore this further when looking 
at  hospitalization  rates  for  other  diseases.  The  same  pattern  appears  for  work  absences.  The 
program match effect on time-spent ill is mainly due to decreased absences rather than due to 
shorter hours spent ill per illness. Similar to the results for hospital admissions, the length of time-
spent absent is longer after the program in higher match seasons, although the effect is small and 
indistinguishable from zero. 
                                                 
19 The results for emergency room wait time are around the same magnitude (10 minute decrease) for other types of hospital 
admissions, possibly indicating a slackening of resource constraints. Approximately 60 percent of all hospital admissions are 
admitted through the ER.   26 
5.3 Impact for Age Groups 
Table VI explores patterns among sub groups of the population. It is clear that the young 
and the oldest age groups had the most to gain from the flu shot program. This is true in absolute 
terms and relative to baseline average illness. Young children gain the most relative to baseline 
levels and because this group has the highest incidence of hospitalization for flu (next to those 
over  65),  this  translates  into  large  savings  in  terms  of  hospital  admits.  For  children  under  5, 
relative to an average match, a perfect match brings a gain of 2.0 less hospitalizations per week per 
100,000 for Ontario after the introduction of the flu shot campaign. There are smaller effects for 
middle age groups but the impact begins to increase in the elder age groups of 50 to 65. This group 
had a larger relative increase in vaccination of 13.9 percentage points and exhibits larger decreases 
in illness relative to the younger age group of 25 to 49.  
Figure  VI  shows  the  program  match  effect  over  the  full  age  distribution  for  flu  and 
pneumonia admissions combined and also plots the percent decrease in admissions relative to 
baseline. The greatest percent decreases occur for children under 10 years of age with smaller 
decreases are apparent for prime-age individuals. The decline in hospitalization for ages over 65 is 
substantial both in number and relative to baseline even though there are no relative differences in 
the vaccination for older age. If older groups are unaffected by the vaccination of others, then there 
should be no difference in the relative gain for older adults when the flu shot is a good match in 
Ontario  versus  other  provinces.  However,  as  shown  in  the  figure  and  in  Table  VI,  there  are 
negative effects for all outcomes among older age groups. Relative to baseline, the results are 
smaller than that for children under 18 but represent larger absolute decreases in hospitalization. 
For  instance,  in  older  adults,  relative  to  an  average  match,  a  perfect  match  averts  3.6  flu 
hospitalizations for Ontario over and above city-regions in other provinces.   
Further, I look at the hospitalizations of long-term care residents. Long-term care residents 
have had high vaccination rates since the early 1990s and are particularly at risk for complications 
associated with flu. It is often argued that even with high vaccination rates, this group could 
benefit from vaccination of others due to the low immune response and protection they can sustain 
from the flu shot personally. The program match effect for admissions from care homes, while 
imprecisely measured, indicates that there are large effects here as well: relative to an average 
match, a perfect match averts 16.7 flu hospitalizations per 100,000 residents per week during flu 
season. Relative to baseline levels this is a 27 percent decrease.   27 
One possible explanation for differences in the post program match effect for older adults 
is that the effect may be driven by decreasing returns to vaccination. If there are diminishing 
returns to vaccination (as we might expect given the externality associated with vaccines) then 
there may be differences in illness that are generated solely by differences in baseline vaccination. 
In short, separate groups can have the same increase in flu vaccination but can expect different 
gains in health given current vaccination levels. In this context, this explanation does not explain 
the negative effects I find for older adults in Ontario. Assuming that there are no externality effects 
from other groups, with diminishing returns to vaccination, the gain for older adults in Ontario 
should be smaller compared to city-regions elsewhere. This is because while there were equal 
increases in vaccination in all provinces post program, baseline vaccination levels for these age 
groups are higher in Ontario. When vaccination exhibits diminishing returns, it would imply a 
positive post program match effect. Instead, there is a negative post program match effect, and the 
remaining explanation is that older groups in Ontario benefited from the externality associated 
with vaccination of younger groups. The effect may be even larger when baseline vaccination 
levels are more comparable to the other provinces. 
 
5.4 Impact for Other Health Outcomes 
  It  is  clear  that  the  flu  shot  program  can  affect  the  more  serious  health  complications 
associated  with  hospital  admission  but  I  now  explore  impacts  for  less  severe  outcomes  using 
health survey data. A subset of health surveys (summarized in Table I) include information on 
recent fluctuations in health. Each respondent is asked if they spent time in bed or reduced activity 
due to illness during the last two weeks. Respondents are also asked detailed questions about 
medications taken in the last month and these responses can be categorized by DIN number into 
different medicine types. Using this information, I generate a variables indicating reduced activity 
or bed illness and use of over-the-counter medications for cold or flu. Furthermore, by using the 
date of survey, I can divide the data into time spans during flu season and those during off-season. 
Unlike observations in the hospitalization data, these surveys are designed to be representative of 
the underlying population and can be used to analyze the general impact of the flu shot program. 
Results for these outcomes for full and sub samples are given in Table VII. For the full sample, 
there is a negative effect for both medications and bed illness. During flu season, a good match flu 
shot decreases medications for cold/flu by 10.2 percentage points for Ontario relative to the other   28 
provinces.
20 There is a 3.0 percentage point fall in the rate of being recently in bed ill. This is 
compared to a 6.8 percentage point decrease in laboratory confirmed flu rate. The larger effect for 
laboratory flu rates may be explained by methods of testing. These lab tests are not collected 
through random sampling of the population but are instead collected from sentinel physicians and 
may have different sensitivities or specificities to true underlying flu. Likely, there is a higher 
proportion of flu incidence in this sample than in a random sample of the population. Furthermore, 
testing behaviors may be related to both the match rate and the immunization campaign, which 
could bias the result found here. 
Patterns  within  age  groups  exhibit  the  same  patterns  as  for  work  absences  and 
hospitalizations: effects are largest for the youngest and oldest, with modest effects for those ages 
25 to 64. Results for the sample of workers corroborates previous results from the Labour Force 
Survey. There is a 0.54 percentage point decrease in recent bed illness during the flu season for the 
sample of workers from the health surveys, which corresponds approximately to a 0.59 percentage 
point decrease in work absences for the same sub group using the Labour Force Survey. 
 
5.5 Impact on Respiratory Versus Non-respiratory Admissions 
  Next I examine how other admissions are impacted by the flu shot program. Flu is known 
to cause complications for a number of diseases, for instance: heart diseases, chronic respiratory 
problems,  cancer,  disease  of  the  nervous  system  and  other  conditions  associated  with 
immunosupression. To analyze the impact of the flu shot program on these diseases, I divide the 
admissions data into two categories: hospitalizations that contain a co-diagnosis of respiratory 
disease  and  hospitalizations  that  do  not.  Panel  A  in  Table  VIII  shows  results  for  respiratory 
diagnoses and indicates that respiratory hospitalizations are sensitive to the post program match 
effect. For instance, the average rate of hospitalization for respiratory disease is 32.2 per week 
during the flu season and is 24.8 in off-season. During the flu season, the program match effect is 
a decrease of 9.6 respiratory hospitalizations over and above city-regions outside Ontario, while 
the effect is small and statistically insignificant from zero in the off-season. Looking at other 
diseases,  similar  patterns  emerge.  Except  for  cancer,  the  post  program  match  effect  is  largest 
during the flu season and small and indistinguishable from zero in the off-season. There is no 
effect on cancer patients in either the flu season or off-season. Panel B of the table reports results 
                                                 
20 As a side note, there was no impact, positive or negative, on the use of antibiotics.   29 
for hospitalizations that do not have a contributory diagnosis of respiratory disease. Here there are 
no visible patterns among diseases both during flu season and off flu season: all point estimates 
are small relative to the mean and indistinguishable from zero. This has two implications. First, 
there are no observable differences in patterns of health that are not associated with the flu or flu 
complications. We would expect that if general health were correlated in some way with the flu 
shot match specific to the time and place of the introduction of the immunization program, it 
would manifest in some other measures of health. The evidence shown here indicates that the 
impact of the program is specific to flu and its complications and moreover, follows the timing of 
elevated circulation of flu. Secondly, there seems to be no evidence that the flu shot program 
decreases crowd out of other disease admissions in any statistically significant way.   
 
6 Interpretation 
Are the estimates presented plausible for the effect of vaccination on flu incidence? Based 
on approximations of the transmission rate and duration rate of the flu, an infected individual 
mixing  in  a  wholly  unvaccinated  population,  would,  on  average,  infect  1.44  before  recovery 
(Hethcote 2000). A simple model of disease dynamics indicates that a fully protective vaccine and 
a vaccination rate greater than 31 percent will reduce the average infection number below one.
21 In 
other words, an infected individual will less than replace himself with a new infection and a flu 
epidemic will be prevented. Average vaccination rates in Ontario increased from 21 percent to 42 
percent post program. Based on these numbers the expected effect of the immunization program 
should be large when the vaccine is of full protective value. Given a perfect vaccine match and the 
increases in vaccination following the immunization campaign, results show that the rate of flu 
hospitalizations decreased by 2.0 in flu season weeks. Relative to baseline levels, this is a 67 
percent  decrease.  At  the  average  match  rate,  this  represents  a  47  percent  decrease.  There  is 
evidence that part of this effect is due to externalities from vaccination. For those 65 and older 
there was an 85 percent decrease (60 percent at average match) in hospitalizations relative to 
baseline levels. Illness absences for workers decreased 0.6 percentage points. Relative to the 10 
percentage point increase in vaccination for this group, this implies that during the flu season when 
the flu shot is a good match, a vaccinated worker is 6 percent less likely to be absent from work 
                                                 
21 This model is based on the Kermack and McKendrick Susceptible-Infective-Removed model of disease epidemics. Several 
variations of the model are shown in: Kremer and Snyder (2006), Geoffard and Philipson (1997), Francis (1997, 2004) and Boulier, 
et al. (2007).   30 
for reasons of illness following the immunization campaign. 
These  results  suggest  that  the  flu  shot  may  have  substantial  benefits  in  terms  of 
hospitalization  and  lost  work  costs.  For  instance,  estimates  indicate  that  9.6  respiratory 
hospitalizations per 100,000 are prevented per week during the flu season over the population of 
Ontario. This is a savings of 1,245 admissions per week. The length of the average flu season is 
9.4 weeks and the cost of an average respiratory hospitalization is $8,629 (CIHI 2008). A back of 
the envelope calculation indicates a savings of $101m when the match is perfect. At the average 
match rate of 71 percent, this represents a savings of $72m. For illness absences, estimates indicate 
there  was  a  0.6  percentage  point  decrease  in  work  absences  over  the  working  population  of 
Ontario. This is a savings of 47,400 work absences per week. At an average hourly wage of $18 
and average absence duration of 9.1 hours this translates into $73m in savings per season for 
Ontario in perfect match years ($52m at the average match). These saving are less than total 
program costs. As part of the program 6 million vaccinations were distributed in Ontario per 
season. This represented an average $19m in additional administration costs and an extra $14m in 
vaccine costs for a total additional cost of $33m per season.  
 
7 Conclusion 
  I evaluate the health and economic consequences of a broad-scope immunization program: 
one of the first to recommend and provide the vaccine to all children and adults under 65. Since 
this program was one of the first of its kind, it provides novel evidence on the consequences of 
immunization for younger age groups and results reflect on the total impact for all groups and the 
externality effects for older age groups. 
  The  study  design  benefits  from  a  number  of  factors:  (1)  variation  in  the  timing  of  a 
program that was pervasive and effective at increasing vaccination, (2) exogenous variation in the 
match of the flu shot that permits a treatment control design, and (3) comprehensive data on 
measures of health and productivity that span a number of seasons across numerous well-defined 
geographical areas. In contrast to existing literature that does not rule out other correlated effects, I 
find significant decreases in flu and pneumonia hospitalizations and provide evidence of the same 
for work absences and other health outcomes such as bi-weekly bed illness and monthly over the 
counter cold and flu medicines. Moreover, the research design implies that these results operate 
only through the impact of increased vaccination; the effect is identified through variation in the   31 
efficacy of the flu shot whilst controlling for differences across time and region and differential 
effects of the match across time and province. 
  For those under 65, the impact was largest for children and the older age group of 50 to 65 
years. This pattern is apparent in all outcomes studied and follows the pattern of vaccination 
uptake  after  program  introduction.  Further  to  this,  significant  effects  were  found  for  the 
hospitalizations  of  older  adults  (65  and  older)  and  long-term  care  residents,  both  of  whom 
experienced no significant relative increases in vaccination. I argue that this is evidence that these 
groups experienced external effects from the vaccination behavior of younger individuals living 
within the same geographical region. This is further supported by the negative effects for bi-
weekly bed illness and monthly consumption of medicines for ages 65 and over. For the working 
population, there is a .6 percentage point decrease in work absences due to illness (22 percent 
decrease from baseline). This is corroborated by results from health surveys that indicate that 
decreases in recent bed illness for the same population were of the same magnitude. 
  This study contributes to two important questions. The first deals with the expected gains 
from  vaccination  of  healthy  children  and  younger  adults;  are  there  sufficient  benefits  from 
vaccination to recommend or even subsidize its use? I provide results that indicate that a flu shot 
with a good match can have a significant impact on the health and economic outcomes of these 
groups  with  still  large  benefits  at  the  average  match  rate.  This  is  true  both  for  severe  health 
outcomes such as hospitalization but also measures of productivity such as worker absenteeism. 
The second question deals with the expected gains for older groups; does vaccination of children 
and young adults impact the health of older individuals? I provide evidence of external effects of 
vaccination  of  younger  groups  on  the  health  of  older  groups.  The  flu  shot  program  led  to 
significant benefits for older adults. This is true for all ages over 65 as well as long term care 
residents. Since these effects are substantial, in the very least, they imply that care must be taken to 
address possible treatment spillovers in other contexts. 
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 Variables Data source Time period Frequency
Vaccination status Statistics Canada:                                      
NPHS Cycle 2, CCHS Cycles 1.1, 2.1, 3.1***
1996-2006          
(with gaps) yearly
In bed due to illness Statistics Canada:                                         
NPHS Cycles 1 - 3, CCHS Cycles 1.1, 2.1, 3.1
1994-2006          
(with gaps) bi-weekly
Over the counter cold/ flu 
medicines
Statistics Canada:                                          
NPHS Cycles 1 - 6
1994-2006          
(with gaps) monthly
Laboratory confirmed flu Public Health Agency of Canada 1995-2006 weekly
Strain isolation of flu subtypes Public Health Agency of Canada 1995-2006 yearly
Antigenic match: flu shot to 
strains of flu Canadian Communicable Disease Report* 1995-2006 yearly
Hospitalizations Canadian Institute for Health Information:                                      
Hospital Morbidity Database**                              1996-2006 weekly
Worker absence Statistics Canada:                                        
Labor Force Survey  1995-2006 monthly
Public health expenditure Canadian Institute for Health Information: 
National Health Expenditure Database 1996-2006 yearly
Hospital bed counts Canadian Institute for Health Information: 
Canadian MIS Database 1999-2006 yearly
Population counts Statistics Canada:                                     
Population and Demography 1996-2006 yearly
Population in care facilities Statistics Canada:                                     
Residential Care Facilities Survey 1996-2006 yearly
* Confirmed using data from the Center for Disease Control in the U.S. and the World Health Organization
** Quebec and rural Manitoba not included
*** NPHS = National Population Health Survey and CCHS = Canadian Community Health Survey
TABLE I
Summary of Data Sources
35  Ontario
  Pre Post Change Pre Post Change
Full Sample 0.208 0.417 0.209 0.170 0.291 0.122 0.087 *** 0.023
Under 65 0.120 0.333 0.213 0.092 0.197 0.105 0.108 *** 0.005
65 and over 0.609 0.737 0.128 0.521 0.645 0.124 0.004   0.029
Male 0.111 0.292 0.181 0.076 0.169 0.093 0.088 *** 0.021
Female 0.128 0.369 0.241 0.107 0.222 0.115 0.127 *** 0.023
No secondary graduation 0.167 0.338 0.172 0.103 0.168 0.065 0.106 *** 0.025
Secondary graduation 0.101 0.308 0.207 0.075 0.162 0.087 0.120 *** 0.019
Some post-secondary 0.100 0.290 0.190 0.093 0.171 0.079 0.111 *** 0.021
Post-secondary graduation 0.113 0.346 0.233 0.097 0.231 0.135 0.098 *** 0.024
Income <$30K 0.130 0.350 0.220 0.101 0.186 0.085 0.135 *** 0.021
Income $30K-$50K 0.118 0.336 0.218 0.087 0.192 0.105 0.113 *** 0.022
Income >$50K 0.109 0.324 0.215 0.085 0.205 0.120 0.095 *** 0.024
Full time worker 0.096 0.301 0.205 0.079 0.187 0.108 0.097 *** 0.021
Part time worker 0.112 0.342 0.230 0.087 0.188 0.101 0.129 *** 0.021
Not in labor force 0.187 0.448 0.262 0.149 0.263 0.114 0.147 *** 0.023
               
No chronic conditions 0.085 0.267 0.182 0.061 0.143 0.082 0.100 *** 0.020
At least one condition 0.237 0.479 0.241 0.201 0.326 0.126 0.116 *** 0.028
               
SRH: excellent/very good 0.095 0.302 0.207 0.072 0.174 0.102 0.105 *** 0.023
SRH: good 0.138 0.356 0.217 0.103 0.209 0.106 0.112 *** 0.021
SRH: fair/poor 0.256 0.455 0.199 0.213 0.304 0.091 0.107 *** 0.024
               
Full sample obs. 40,012 119,294 159,306 31,824 144,774 176,598
Std.    
error
Flu Vaccination Rates by Selected Characteristic
TABLE II




Statistics are calculated using the master files of the NPHS cycle 2 and CCHS cycles 1.1, 2.1, 3.1. Pre and post denote before and after October
2000. Vaccination rates for each sub-group are shown pre-post program in Ontario and other regions in Canada (excluding Quebec, rural
Manitoba, and the Territoires). The relative change in vaccination for Ontario versus other regions is displayed in the second last column with
robust standard errors clustered by province shown to the right of the estimate. Chronic conditions include Asthma, Heart Disease, High Blood
Pressure, Diabetes, Cancer, Emphysema/Chronic Bronchitis. SRH stands for self-rated health. * p<0.10, ** p<0.05, *** p<0.001. 
Panel A: Vaccination by age group
Panel B: Vaccination under 65 by demographic characteristic and health status
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  Mismatch Match Mismatch Match Mismatch Match Mismatch Match
All weeks 0.524 0.450 9.451 9.339 60.237 62.387 0.0262 0.0221
  (0.015) (0.012) (0.046) (0.052) (0.175) (0.208) (0.0001) (0.0001)
Season start to peak 2.280 1.572 13.359 13.204 58.354 62.818 0.0287 0.0238
  (0.102) (0.073) (0.187) (0.207) (0.517) (0.656) (0.0003) (0.0003)
Season end 1.177 0.760 11.204 10.353 58.158 63.089 0.0289 0.0234
  (0.081) (0.044) (0.210) (0.161) (0.730) (0.598) (0.0003) (0.0004)
Off-season weeks 0.245 0.266 8.805 8.715 60.647 62.243 0.0255 0.0217
  (0.006) (0.007) (0.043) (0.050) (0.192) (0.236) (0.0001) (0.0001)
Post program 0.352 0.300 9.275 9.168 58.221 60.505 0.0299 0.0246
  (0.011) (0.012) (0.054) (0.067) (0.210) (0.295) (0.0001) (0.0002)
Pre program 0.823 0.599 9.756 9.509 63.731 64.269 0.0193 0.0193
  (0.036) (0.020) (0.085) (0.079) (0.299) (0.290) (0.0001) (0.0001)
Ontario 0.367 0.240 8.812 8.848 55.388 57.488 0.0284 0.0234
  (0.019) (0.012) (0.073) (0.081) (0.291) (0.333) (0.0002) (0.0002)
Not Ontario 0.585 0.531 9.699 9.530 62.123 64.293 0.0251 0.0215
  (0.020) (0.015) (0.057) (0.065) (0.209) (0.252) (0.0001) (0.0001)
Full sample size 64,575 46,350 64,575 46,350 64,575 46,350 2,851,884 1,963,596
Age 52.592 48.891 62.002 60.680 58.559 58.040 48.088 47.832
  (0.202) (0.252) (0.038) (0.043) (0.012) (0.013) (0.036) (0.048)
Fraction male 0.446 0.431 0.532 0.538 0.519 0.518 0.319 0.330
  (0.003) (0.004) (0.001) (0.001) (0.000) (0.000) (0.002) (0.002)
Duration 7.193 6.345 9.919 10.301 8.751 8.948 9.073 9.174
  (0.095) (0.156) (0.031) (0.039) (0.009) (0.011) (0.037) (0.049)
Wait time in ER 4.878 4.969 4.774 4.823 4.244 4.654    
  (0.062) (0.139) (0.011) (0.019) (0.005) (0.008)    
Fraction with death 0.038 0.022 0.139 0.142 0.043 0.045    
  (0.001) (0.001) (0.000) (0.001) (0.000) (0.000)    
Care home resident 0.064 0.047 0.098 0.100 0.037 0.039    
  (0.002) (0.002) (0.000) (0.000) (0.000) (0.000)    
Urban postal code 0.786 0.756 0.864 0.860 0.870 0.866    
  (0.003) (0.003) (0.000) (0.001) (0.000) (0.000)    
Sample size 30,516 16,095 552,272 435,438 3,504,633 2,958,813 74,586 43,308
Source data: HMDB; author's calculation LFS; author's calculation
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Variable means displayed with standard error of the mean given in parentheses below. Hospitalization admission rates are calculated per 100,000
per week for different age groups across city-regions using data from the HMDB. Work absences are short term work absences for reasons of
personal illness during a reference week and these data are collected from the LFS. Season periods are defined according to flu surveillance data
from the PHAC. Non respiratory diagnoses include all hospitalizations that do not list a respiratory diagnosis as an MRD (most responsible
diagnosis) or as a contributing diagnosis. Statistics are weighted by population cell size (HMDB) or survey weights (LFS). In Panel B, average
characteristics of each illness incident are given. Average duration for hospital admissions is in days and average duration for work absences is in





Illness                   
work absence
Flu                
admissions
Pneumonia        
admissions
Panel A: Weekly incidence rate
Panel B: Individual characteristicsDependant Variables:
(1)            
Average 
duration
Season start to peak 5.3 weeks -2.829 ** -4.693 * -0.0050 *
(0.750) (2.461) (0.0026)
3.053 15.716 0.0267
Season end 4.1 weeks -2.421 ** -4.917 ** -0.0079 *
(0.661) (1.615) (0.0042)
2.996 12.454 0.0276
Off season 42.6 weeks -0.006   -0.336 -0.0009  
(0.032) (0.204) (0.0010)
0.344 8.750 0.0249
Season start to peak -2.835 ** -4.726 * -0.0060 **
(0.774) (2.351) (0.0023)
Season end -2.440 ** -4.760 ** -0.0078 *
(0.694) (1.676) (0.0042)
Off season -0.009   -0.307 -0.0009  
(0.032) (0.221) (0.0010)
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Panel A: Basic Results
Panel B: Account for behavioral response to match by controlling for circulation of other infectious disease
TABLE IV
The Flu Immunization Campaign, Vaccine Match and Health Outcomes
(2)                         
Flu                                  
admissions
(3)                      
Pneumonia 
admissions
(4)                        
Illness                  
work absence
This table reports estimates of the interaction of the clinical match rate, a post October 2000 dummy and a dummy for city-regions in Ontario.
Table columns report results for different health outcomes and rows report results for three different periods during the year: the flu season start to
peak, the flu season end, and the flu off-season. Column (1) shows the average duration of each different period. Each estimate shown in Column
(2) to (4) is a separate regression. Robust standard errors are given in parentheses and are allowed to be correlated within province clusters (*
p<0.10, ** p<0.05, *** p<0.001). The baseline mean of the dependent variable is given below the standard error of each estimate. The dependent
variables are listed in the table headings. Flu admissions denote hospital admissions per 100,000, per week where flu was either the MRD (most
responsible diagnosis) or other contributing diagnosis and pneumonia admissions denote hospital admissions per 100,000, per week where
pneumonia was either the MRD or other contributing diagnosis (source data from the HMDB). Work absences are short term work absences for
reasons of personal illness during a reference week (source data from the LFS). Regressions are weighted by cell size (admissions) or survey
weight (absences). All regressions include the level effect of the match rate, month, age, season and city-region fixed effects as well as
interactions of PostXMatch, PostXOntario, and OntarioXMatch. Regressions in columns (2) and (3) also control for public health expenditures on
health care (hospitals, capital investments, physicians and other health professionals), diagnosis specific coding classifications changes (ICD10
versus ICD9) and the proportion of observed strains of each of H1N1, H3N3 and B in each season. Regressions in column (4) control for the
same factors and for education, marital status, sex, occupation and union status. Results in Panel B control for surveillance rates of other
infectious respiratory disease (respiratory syncytial virus, parainfluenza, and adenovirus).Dependant Variables:
Death
Flu season -0.121 ** -0.560 **
(0.027) (0.127)
0.122 1.459
Off season 0.002   -0.042  
(0.003) (0.054)
0.006 1.098
Wait time in ER
Flu season -0.161 -0.136
(0.240) (0.588)
3.774 3.539




Flu season -15.365 ** -39.477 ** -0.0383 *
(3.596) (14.378) (0.0189)
23.232 124.024 0.1780




Flu season 3.769 1.751   0.7634
(1.473) (1.321) (1.1668)
7.674 9.562 8.9060




The Flu Immunization Campaign, Vaccine Match and Time Lost to Illness
This table reports estimates of the interaction of the clinical match rate, a post October 2000 dummy and a dummy for city-regions in Ontario.
Table columns report results for different health outcomes and rows report results for death and different time factors associated with illness.
Time spent ill is measured in days in the case of hospital admissions and hours in the case of work absences. Each estimate is a separate
regression. Robust standard errors are given in parentheses and are allowed to be correlated within province clusters (* p<0.10, ** p<0.05, ***
p<0.001). The baseline mean of the dependent variable is given below the standard error of each estimate. The dependent variables are listed in
the table headings. Flu admissions denote hospital admissions per 100,000, per week where flu was either the MRD (most responsible diagnosis)
or other contributing diagnosis and pneumonia admissions denote hospital admissions per 100,000, per week where pneumonia was either the
MRD or other contributing diagnosis (source data from the HMDB). Work absences are short term work absences for reasons of personal illness
during a reference week (source data from the LFS). Regressions are weighted by cell size (admissions) or survey weight (absences). All
regressions include the level effect of the match rate, month, age, season and city-region fixed effects as well as interactions of PostXMatch,
PostXOntario, and OntarioXMatch. Regressions in columns (1) and (2) also control for public health expenditures on health care (hospitals,
capital investments, physicians and other health professionals), diagnosis specific coding classifications changes (ICD10 versus ICD9), the
proportion of observed strains of each of H1N1, H3N3 and B in each season, and surveillance rates of other infectious respiratory disease
(respiratory syncytial virus, parainfluenza, and adenovirus). Regressions in column (3) control for the same factors and for education, marital
status, sex, occupation and union status. 
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(1)                                     
Flu admissions
(2)                        
Pneumonia admissions
(3)                                
Illness work absenceLess than 5 years -6.939 ** -14.012 **    
(1.796)   (4.674)        
6.155   25.443        
5 to 11 years -1.180 ** -1.228 *      
(0.482)   (0.642)        
1.658   3.941        
12 to 19 years
1 -0.450 * -1.366 ** -0.0090 0.093 ***
(0.196)   (0.508)   (0.0163)   (0.017)
0.980   1.598   0.0250   0.167
20 to 24 years -0.214   -1.073   -0.0179 ** 0.085 ***
(0.154)   (0.644)   (0.0068) (0.011)
0.823   1.680   0.0330 0.065
25 to 49 years -0.513   -1.768 ** -0.0054 ** 0.092 ***
(0.297)   (0.389)   (0.0024) (0.010)
1.031   2.930   0.0320 0.076
50 to 64 years -1.925 ** -4.380 ** -0.0076 *** 0.129 ***
(0.565)   (0.936)   (0.0015) (0.011)
2.576   9.751   0.0140 0.256
65 or more years -11.969 ** -21.283 ** -0.0036 0.004
(3.577)   (6.794)   (0.0066)   (0.009)
14.765   53.718   0.0090   0.609
Nursing home resident -57.648   -157.831  
(37.779) (104.272)
62.008 137.309
All ages -2.006 ** -5.140 ** -0.0059 ** 0.087 ***
(0.546) (1.138) (0.0022) -0.023
3.016 10.914 0.0274 0.191      
1 This age group is 15 to 19 for work absences.
See notes for Table IV. Columns (1) to (3) report estimates of the interaction of the clinical match rate, a post October 2000 dummy and a
dummy for city-regions in Ontario for different sub-groups. Column (4) reports estimates of the interaction between a post October 2000
dummy and a dummy for city-regions in Ontario for the outcome of vaccination. Each estimate is a separate regression for the sub-group
indicated. Regressions are weighted by cell population or survey weight. Robust standard errors are given in parentheses and are allowed to be
correlated within province clusters (* p<0.10, ** p<0.05, *** p<0.001). The baseline mean of the dependent variable is given below the
standard error of each estimate. The dependent variables are listed in the table headings. 
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TABLE VI
Results for Sub-groups During Flu Season
(1)                            
Flu admissions
(2)                 
Pneumonia 
admissions
(3)                    
Illness work                 
absence
(4)               
VaccinationDependent variable:
(1)                    
Weekly        
laboratory 
confirmed flu rate
(2)                     
Cold or flu 
medicine in last 
month
(3)                          
In bed due to      
illness in last two 
weeks
(4)                       
Work absence due 
to illness in last 
week
All  -0.068 -0.102* -0.030*
(0.064) (0.052) (0.017)
Baseline mean 0.202 0.769 0.097
Observations 1,197 18,981 72,974
Workers -0.105 -0.005 -0.006**
(0.066) (0.016) (0.002)
Baseline mean 0.737 0.097 0.027
Observations 10,143 45,220 919,830
25 and younger -0.105 -0.112***
(0.073) (0.027)
Baseline mean 0.841 0.130
Observations 6,525 12,629
25 to 64 years -0.040 -0.010
(0.079) (0.020)
Baseline mean 0.740 0.100
Observations 9,728 46,057
65 and older -0.368** -0.055**
(0.156) (0.018)
Baseline mean 0.697 0.061
Observations 2,728 14,288
Data Source: PHAC NPHS:1-6
NPHS:1-3,         
CCHS:1.1-3.1 LFS 1995-2006
TABLE VII
Results for Other Health Outcomes During Flu Season
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See notes for Table IV. This table reports estimates of the interaction of the clinical match rate, a post October 2000 dummy and a dummy for city-
regions in Ontario for weeks during flu season. Table columns report results for different dependent variables and rows report results for different
sub-groups. For laboratory confirmed flu rate (column [1]), regressions control for interactions of PostXMatch, PostXOntario, OntarioXMatch, 
season, province, age, and month effects, in addition to other base specification controls. Regressions for outcomes in columns (2) to (4) include
interactions of PostXMatch, PostXOntario, OntarioXMatch, season, city-region, age, and month effects, in addition to other base specification
controls. Each estimate is a separate regression. Regressions are weighted by cell population or survey weight. Robust standard errors are given
in parentheses and are allowed to be correlated within province clusters (* p<0.10, ** p<0.05, *** p<0.001). The baseline mean of the dependent
variable is given below the standard error of each estimate and sample size is given below the mean. Dependent variable:
(1)           
Respiratory 
disease
(2)                 
Heart disease
(3)                 
Cancer
(4)                 
Mental disease
(5)                 
Disease of the 
nervous system
Flu season -9.579** -2.756** 0.044 -1.605*** -0.212**
(2.100) (0.737) (0.196) (0.317) (0.078)
32.244 12.643 2.790 4.308 0.645
Off season -1.796 -0.553 -0.021 -0.338 -0.030
(1.354) (0.349) (0.124) (0.216) (0.020)
24.847 10.208 2.626 3.500 0.500
Flu season 0.280 0.474 -0.084 -0.077
(1.185) (0.324) (0.543) (0.087)
25.342 9.264 13.347 1.045
Off season 0.725 0.209 -0.074 -0.077
(0.457) (0.135) (0.325) (0.057)
25.469 9.627 13.293 1.060
See notes for Table IV. Columns (1) to (5) report estimates of the interaction of the clinical match rate, a post October 2000 dummy and a dummy
for city-regions in Ontario. Each estimate is a separate regression for the dependent variable and the time period indicated. Panel A includes
admissions with a contributory diagnosis of respiratory disease and Panel B includes admissions without a contributory respiratory diagnosis.
Regressions are weighted by cell population. Robust standard errors are given in parentheses and are allowed to be correlated within province
clusters (* p<0.10, ** p<0.05, *** p<0.001). The baseline mean of the dependent variable is given below the standard error of each estimate. 
TABLE VIII
Results for Other Disease Outcomes
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Panel B: Admissions without diagnosis of respiratory disease
Panel A: Admissions with co-diagnosis of respiratory diseaseFIGURE I
Flu Vaccination for Flu Seasons 1996/1997 to 2006/2007
The y axis plots the average vaccination for each flu season-year based on master file data from the National Population
Health Survey Cycle 2 and the Canadian Community Health Survey Cycles 1.1, 2.1, 3.1. Vaccination rates are given by














96/97  97/98  98/99  99/00  00/01  01/02  02/03  03/04  04/05  05/06  06/07 
Regions in Ontario 65+ (fitted)   Regions in Ontario 65+ 
Regions outside Ontario 65+ (fitted)  Regions outside Ontario 65+ 
Regions in Ontario <65 (fitted)   Regions in Ontario <65 
Regions outside Ontario <65 (fitted)  Regions outside Ontario <65 FIGURE II
Clinical Match Rate and Infectious Disease Surveillance
In Panel A, the average clinical match rate is shown for each season with error bars indicating two standard deviations
from the mean (variaton is between province). The clinical match rate is calculated from the yearly Canadian
Communicable Disease Report and strain isolation data from the PHAC. Panel B shows the average weekly fraction of
infectious disease tests that are positive for flu. These data are collected through the disease surveillance program of the
PHAC. For each year, week 40 (roughly the first week in October) is marked by a tick on the x axis. The period of high
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Panel B: Laboratory Confirmed Flu 












94/95  95/96  96/97  97/98  98/99  99/00  00/01  01/02  02/03  03/04  04/05  05/06 
Panel A: Clinical Match Rate 





Flu Hospital Admissions and the Clinical Vaccine Match
The y-axis plots the seasonal average flu hospital admission rate (per 100,000, per week) and the x-axis plots the seasonal
clinical match rate for the flu vaccine. Data are calculated using the HMDB (for hospital admissions) and the PHAC and
CCDR (for the match rate). Each point represents the year specific average flu admission rate and the corresponding average
match rate for city-regions in and outside of Ontario. The lines are fitted values from regressions of the flu admission rate on
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Regions outside Ontario (fitted) 
Regions outside Ontario 









0.00  0.25  0.50  0.75  1.00 
Pre program The top two graphs plot the average weekly hospital admission rate per 100,000 for flu and the bottom two plot the average
weekly hospital admission rate for pneumonia (adjusted for ICD9 to ICD10 coding changes). Data are calculated using the
HMDB. The dark line is the weekly average for city-regions in Ontario and the light line is the weekly average for city-
regions in other provinces. The left side of the figure plots weekly rates for flu seasons with a mismatch in the flu vaccine and
the right side of the figure plots weekly rates for seasons without a mismatch in the flu vaccine. For each year, week 40
(roughly the first week in October) is marked by a tick on the x axis. The immunization program in Ontario came into effect
in week 40 of year 2000.
FIGURE IV
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Hospital Admissions: Flu 
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Hospital Admissions: Flu 
Flu Seasons with Vaccine Mismatch 
Program 
Change FIGURE V
Work Absenteeism and Flu Surveillance by Season and Vaccine Match
The top two graphs plot the average work absence rate for reasons of personal illness over months occurring in five
different periods during the flu season: the fall (pre) season, season start, season peak, season end, and the summer (post)
season. The dark line is the period average for workers in Ontario and the light line is the period average for workers in
other provinces. Data are from successive months of the LFS. The y axis of the bottom two graphs plot the fraction of
weekly surveillance tests that are positive for flu. These data are from the PHAC surveillance program. The dark line is
the weekly flu surveillance rate in Ontario and the light line is the average weekly flu surveillance rate in the other
provinces. For each year, week 40 (roughly the first week in October) is marked by a tick on the x axis. The left side of
the figure plots work absence and flu surveillance rates for flu seasons with a mismatch in the flu vaccine and the right
side of the figure plots weekly rates for seasons without a mismatch in the flu vaccine. The immunization program in
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Work Absence: Personal Illness 
Program 
Change 
Flu Seasons with Vaccine Mismatch FIGURE VI
Vaccine Program Match Effect on Combined Flu and Pneumonia Admissions by Age Group
The y-axis on the left plots the age specific coefficients on the program match effect (the interaction of the clinical match rate,
a post October 2000 dummy and a dummy for city-regions in Ontario) for flu and pneumonia admissions combined (rate per
100,000, per week). The dark solid line indicates the decline in admissions for each age group during the flu season with
confidence intervals indicated by error bars for each coefficient estimate. For comparison, the dotted line shows the program
match effect for each age group during the off-season period. The y-axis on the right shows the decline in admissions as a
percent of the baseline admission rate and the light grey line shows the percent decline from baseline for each age group. Data
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Age 